Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL)
Health Care · Pharmaceuticals · US
$5.93
-4.59% today · -35.2% 1Y
Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $13.32M and employs 5 people.
Over the last twelve months the share price has lost 35.2%, trading between 1.31 and 10.75.
Tweenvest scores Adial Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ADIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -28.91
- Dividend yield
- —
- Beta (5Y)
- 1.29
- 52-week high
- $10.75
- 52-week low
- $1.31
- Avg volume (3M)
- —
- Shares outstanding
- 2.14M
- Employees
- 5
- Next earnings
- —
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
- ISIN
- US00688A3041
- Founded
- 2010
- Listed since
- Jul 27, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,232.30 | -1.17% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.64 | -0.15% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.40 | +3.81% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.52 | +1.97% |
Figures last refreshed Aug 18, 2026.